首页> 外文期刊>Bone marrow transplantation >Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
【24h】

Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.

机译:氟达拉滨,氨苯磺酸,大剂量阿糖胞苷和全身照射12 Gy,然后进行同种异体造血干细胞移植,对于复发或高危急性淋巴细胞白血病患者有效。

获取原文
获取原文并翻译 | 示例
           

摘要

In this prospective study, we examined the toxicity and efficacy of an intensified conditioning regimen for treatment of patients with relapsed or high-risk acute lymphoblastic leukemia who undergo allogeneic hematopoietic stem cell transplantation. Fifteen patients received fludarabine 30 mg/m(2), cytarabine 2000 mg/m(2), amsacrine 100 mg/m(2) on days -10, -9, -8 and -7, anti-thymocyte globulin (ATG-Fresenius) 20 mg/kg body weight on days -6, -5 and -4 and fractionated total body irradiation 2 x 2 Gy on days -3, -2 and -1 (FLAMSA-ATG-TBI) before allogeneic hematopoietic stem cell transplantation. At the time of hematopoietic stem cell transplantation, 10 patients were in complete remission (8 CR1; 2 CR2), 3 with primary refractory and 2 suffered from refractory relapse. All patients achieved a complete remission after hematopoietic stem cell transplantation; and after a median follow-up time of 1091 days (range, 334-1554 days), nine patients (60%) are alive and free from disease, including three patients with prior refractory disease. Three patients died due to treatment-related mortality. The most frequent and severe conditioning-related toxicities observed in 9 out of 15 patients were grade III/IV infections according to common toxicity criteria. Thus, conditioning with the FLAMSA-ATG-TBI regimen is a feasible and effective alternative for patients with relapsed or high-risk acute lymphoblastic leukemia.
机译:在这项前瞻性研究中,我们检查了强化调理方案对异基因造血干细胞移植治疗复发性或高危急性淋巴细胞性白血病患者的毒性和疗效。十五名患者在第-10,-9,-8和-7天接受了氟达拉滨30 mg / m(2),阿糖胞苷2000 mg / m(2),amsacrine 100 mg / m(2),抗胸腺细胞球蛋白(ATG- Fresenius)在异体造血干细胞移植前的第-6,-5和-4天为20 mg / kg体重,在-3,-2和-1天为2 x 2 Gy(FLAMSA-ATG-TBI)进行分次全身照射。造血干细胞移植时,10例患者完全缓解(8例CR1、2例CR2),3例原发性难治性患者和2例难治性复发患者。所有患者在造血干细胞移植后均完全缓解;在中位随访时间为1091天(范围为334-1554天)后,有9名患者(60%)还没有疾病并且还活着,其中包括3名先前患有难治性疾病的患者。三例患者死于与治疗有关的死亡率。根据常见毒性标准,在15名患者中有9名最常见和最严重的与条件相关的毒性是III / IV级感染。因此,对于复发或高危急性淋巴细胞白血病患者,用FLAMSA-ATG-TBI方案进行调理是一种可行而有效的选择。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号